BioSpace News Archive

IMV Inc. to Present at Two Upcoming Investor Conferences

IMV Inc., a clinical stage immuno-oncology company, announced that IMV Chief Executive Officer Frederic Ors will present at the Spring Investor Summit and the HC Wainwright Global Life Sciences Conference during April 2019.

March 25, 2019
·
1 min read
Job Trends

Castle Biosciences Announces Presentation of 5-Year Prospective, Multicenter Clinical Outcome Study Confirming Accuracy and Impact of Uveal Melanoma Test

Data presented at International Society of Ocular Oncology (ISOO) 2019 Conference

March 25, 2019
·
4 min read
Deals

Bristol-Myers Squibb Board of Directors Sends Letter to Shareholders Highlighting the Compelling Strategic and Financial Rationale of the Celgene Transaction; Company Provides Additional Investor Materials

Urges Shareholders to Vote “FOR” the Proposed Transaction on the WHITE Proxy Card

March 25, 2019
·
23 min read
Deals

AVROBIO, Inc. Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Provides Business Update

Introduced plato™ platform for worldwide gene therapy commercialization, to be incorporated in AVROBIO-sponsored clinical trials in 2019

March 25, 2019
·
13 min read
Policy

Israel Approves CytoSorb Registration, CytoSorbents Announces Gad Medical as Distributor

CytoSorbents Corporation announces that the Medical Device Division of the State of Israel Ministry of Health medical device regulation unit, has granted registration of CytoSorb in Israel, clearing the way to begin selling the device in the country.

March 25, 2019
·
5 min read
Appili Therapeutics Announces Closing of $3.6 Million Special Warrant Private Placement and Filing of Preliminary Prospectus

- Appili Therapeutics Inc. (“Appili” or the “Company”) is pleased to announce the closing of its private placement offering (the “Brokered Offering”) of special warrants (the “Special Warrants”) for aggregate gross proceeds of $1,944,282

March 25, 2019
·
7 min read
Deals

Ehave Announces Asset Purchase Agreement with Zyus and Recapitalization Transactions

New working capital intended to advance Ehave’s development of digital assessments and therapeutic games for children with ADD/ADHD, ASD, and other mental health disorders.

March 25, 2019
·
5 min read
Deals

Curis to Release Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call on March 26, 2019

Curis, Inc. announced that the Company will release its fourth quarter and full-year 2018 financial results on Tuesday, March 26, 2019, after the close of the US markets.

March 25, 2019
·
1 min read
Biotech Bay

Alkahest Presents Positive Results from Phase 2a Open Label Study of AKST4290 in Treatment-Naïve neovascular AMD at Retina World Congress

Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, shared results yesterday from its open label study, ALK4290-201.

March 25, 2019
·
4 min read
Deals

ZYUS To Acquire Clinical Software Platform from Ehave

Assets to further enhance ZYUS cannabinoid clinical trial program

March 25, 2019
·
4 min read